Section Arrow
Quote
VCRE.NASDAQ
- Vicore Pharma Holding AB
Quotes are at least 15-min delayed:2026/08/31 16:14 EDT
After Hours
Last
 11.55
-- (--)
Bid
4.36
Ask
12
High 11.55 
Low 11.55 
Volume 2 
Regular Hours (Closed)
Last
 11.04
-0.27 (-2.39%)
Day High 
11.04 
Prev. Close
11.31 
1-M High
13.15 
Volume 
9.58K 
Bid
4.36
Ask
12
Day Low
10.7 
Open
10.74 
1-M Low
10.5 
Market Cap 
318.41M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 11.88 
20-SMA 11.74 
50-SMA -- 
52-W High 17.8 
52-W Low 10.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-19.10/--
Enterprise Value
318.41M
Balance Sheet
Book Value Per Share
3.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.82M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.388+0.03+8.38%-- 
After Hours 0.368 -- --
AIMAIM ImmunoTech Inc.0.2309-0.0275-10.64%-- 
After Hours 0.2216 -- --
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 34.64 0 0.00%
CVKDCadrenal Therapeutics Inc1.745+0.205+13.31%-- 
After Hours 1.7 -- --
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.4719 -0.8681 -0.62%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.